These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 20118068)

  • 1. Sevelamer 'carbonate': what's in a name?
    Harland C; Wrong O
    Nephrol Dial Transplant; 2010 Apr; 25(4):1354-5. PubMed ID: 20118068
    [No Abstract]   [Full Text] [Related]  

  • 2. Sevelamer carbonate.
    Barna MM; Kapoian T; O'Mara NB
    Ann Pharmacother; 2010 Jan; 44(1):127-34. PubMed ID: 19955298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V).
    Biggar P; Ketteler M
    Expert Opin Pharmacother; 2010 Nov; 11(16):2739-50. PubMed ID: 20977406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
    Pai AB; Shepler BM
    Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonphosphate-binding effects of sevelamer--are they of clinical relevance?
    Marangon N; Lindholm B; Stenvinkel P
    Semin Dial; 2008; 21(5):385-9. PubMed ID: 18573137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease].
    Runowski D; Jachimiak B; Cieślak-Puchalska A; Pacanowska B; Zimoń T
    Pol Merkur Lekarski; 2009 Apr; 26(154):318-21. PubMed ID: 19580197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of sevelamer carbonate in increasing serum bicarbonate in hyperphosphatemic predialysis patients who have metabolic acidosis.
    Bezzaoucha S; Pichette V; Lafrance JP; Bell R; Laurin LP; Vallée M
    Int J Clin Pharmacol Ther; 2013 Dec; 51(12):989-90. PubMed ID: 24075095
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of phosphate binding by sevelamer carbonate powder for oral suspension mixed in foods.
    Hanus M; Zhorov E; Brommage D; Plone M; Holmes-Farley SR
    Nephrol Nurs J; 2012; 39(3):239-43, 255. PubMed ID: 22866363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Images of the Month: Gastric Pneumatosis Due to Sevelamer-Mediated Necrosis.
    Amer S; Nguyen C; DePetris G
    Am J Gastroenterol; 2015 Jun; 110(6):799. PubMed ID: 26052763
    [No Abstract]   [Full Text] [Related]  

  • 11. Sevelamer reduces the efficacy of many other drugs.
    Prescrire Int; 2009 Aug; 18(102):164-5. PubMed ID: 19743578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
    Ouellet G; Cardinal H; Mailhot M; Ste-Marie LG; Roy L
    Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year experience with sevelamer and calcium salts as phosphate binders.
    Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sevelamer carbonate. No better than sevelamer hydrochloride.
    Prescrire Int; 2010 Jun; 19(107):104-5. PubMed ID: 20738030
    [No Abstract]   [Full Text] [Related]  

  • 17. The control of hyperphosphatemia in renal failure: between vascular calcification and inflammation.
    Cozzolino M
    Blood Purif; 2010; 30(3):159-60. PubMed ID: 20861618
    [No Abstract]   [Full Text] [Related]  

  • 18. Calcium in chronic kidney disease: myths and realities. Introduction.
    Langman CB; Cannata-Andía JB
    Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S1-2. PubMed ID: 20089497
    [No Abstract]   [Full Text] [Related]  

  • 19. [Should we consider the cost-effectiveness analysis to apply the recommendations for phosphate-binders administration?].
    Martín de Francisco AL
    Nefrologia; 2008; 28(2):129-34. PubMed ID: 18454700
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pharmacological and clinical profile of bixalomer (Kiklin(®) capsules): a new therapeutic agent for hyperphosphatemia].
    Taniguchi K; Kakuta H; Tomura Y; Kaku S; Uchida W
    Nihon Yakurigaku Zasshi; 2013 Jun; 141(6):333-7. PubMed ID: 23749074
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.